Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 10/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19778357 | 1.00 | BTN3A1 (0.56) | BTN3A1LMNAHPGDMEN1KMT2A | |
| SCHEMBL15682968 | 1.00 | BTN3A1 (0.56) | BTN3A1LMNAHPGDMEN1KMT2A | |
| SCHEMBL15685881 | 1.00 | BTN3A1 (0.56) | BTN3A1LMNAHPGDMEN1KMT2A | |
| SCHEMBL18512732 | 1.00 | BTN3A1 (0.56) | BTN3A1LMNAHPGDMEN1KMT2A | |
| SCHEMBL12214044 | 1.00 | BTN3A1 (0.56) | BTN3A1LMNAHPGDMEN1KMT2A | |
| SCHEMBL18067176 | 1.00 | BTN3A1 (0.56) | BTN3A1LMNAHPGDMEN1KMT2A | |
| SCHEMBL13656424 | 0.88 | BTN3A1 (0.54) | BTN3A1LMNAHPGDMEN1KMT2A | |
| SCHEMBL14643286 | 0.88 | BTN3A1 (0.54) | BTN3A1LMNAHPGDMEN1KMT2A | |
| SCHEMBL20959996 | 0.88 | BTN3A1 (0.54) | BTN3A1LMNAHPGDMEN1KMT2A | |
| SCHEMBL16015987 | 0.88 | BTN3A1 (0.58) | BTN3A1MEN1KMT2ANPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021129827-A1 | BENZO FUSED RING-BASED COMPOUND | 南京明德新药研发有限公司 | 2021-07-01 | — | — | WO | disclosed |
| EP-2852603-B1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | IDENIX PHARMACEUTICALS LLC (US) | 2021-05-12 | — | — | EP | disclosed |
| EP-3303341-B1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING HIV INFECTION | MERCK SHARP & DOHME (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3285582-B1 | PHOSPHATE-SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20170218007-A1 | A PROCESS FOR THE PREPARATION OF NUCLEOSIDE PHOSPHORAMIDATE | LUPIN LIMITED (IN) | 2017-08-03 | — | — | US | disclosed |
| US-20170128454-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-9580428-B2 | Compositions and methods for inhibiting viral polymerase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150191472-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20070185007-A1 | Aza-quinolinol phosphonate integrase inhibitor compounds | JIN HAOLUN | 2007-08-09 | — | — | US | disclosed |
| US-20070185007-A1 | Aza-quinolinol phosphonate integrase inhibitor compounds | JIN HAOLUN | 2007-08-09 | — | — | US | disclosed |
| US-7253180-B2 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253180-B2 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070072831-A1 | Integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072831-A1 | Integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072831-A1 | Integrase inhibitor compounds | TYMP, CDKN1A, PAICS | BTN3A1 3584/4885LMNA 905/4885HPGD 1068/4885 |
| US-20170128454-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | POLRMT, POLR1E, POLR1A | BTN3A1 4140/4885LMNA 1230/4885HPGD 1670/4885 |
| US-20150191472-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | POLRMT, POLR1E, POLR1A | BTN3A1 4140/4885LMNA 1230/4885HPGD 1670/4885 |
| US-20070185007-A1 | Aza-quinolinol phosphonate integrase inhibitor compounds | CDKL5, CDKL1, CDKL3 | BTN3A1 3294/4885LMNA 1002/4885HPGD 2662/4885 |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | TYMP, PNP, PIKFYVE | BTN3A1 2926/4885LMNA 2126/4885HPGD 1374/4885 |
| US-20170218007-A1 | A PROCESS FOR THE PREPARATION OF NUCLEOSIDE PHOSPHORAMIDATE | SAMHD1, PNP, MTAP | BTN3A1 4450/4885LMNA 3401/4885HPGD 2916/4885 |
| US-20080058315-A1 | Integrase inhibitors | TYMP, DNTT, PAICS | BTN3A1 3196/4885LMNA 907/4885HPGD 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.